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Abstract Proteolysis of insulin-like growth factor binding
proteins (IGFBPs) is the major mechanism of releasing IGFs
from their IGFBP complexes. Analysis of fibroblasts deficient
for the lysosomal cysteine protease cathepsin L (CTSL) revealed
an accumulation of IGFBP-3 in the medium which was due
neither to alterations in IGFBP-3 mRNA expression nor to
extracellular IGFBP-3 protease activity. Incubation of CTSL-
deficient fibroblasts with radiolabeled IGFBP-3 followed by
subcellular fractionation indicates that both intact and fragmen-
ted IGFBP-3 accumulate transiently in endosomal and lysosomal
fractions of CTSL-deficient cells. This suggests the involvement
of CTSL in the intracellular degradation of IGFBP-3 represent-
ing a new mechanism to regulate the extracellular concentration
of IGFBP-3. ß 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The binding of insulin-like growth factors (IGF I and II) to
IGF and insulin receptors initiates various intracellular pro-
cesses resulting in an increased rate of cell proliferation,
growth and di¡erentiation of cells and tissues [1]. The avail-
ability of IGFs is regulated by the presence of six high a⁄nity
IGF binding proteins (IGFBP-1^6). The expression pattern
and secretion of IGFBPs are cell- and tissue-speci¢c, altered
during development, and a¡ected by various cytokines and
hormones [2]. IGFBP-3 is secreted by di¡erent cell types
which may a¡ect IGF actions on cell growth in either an
inhibitory or a stimulatory manner. Furthermore, there is
also evidence that IGFBP-3 inhibits cell growth and is in-
volved in apoptotic processes in an IGF I-independent man-
ner [3,4].
Limited proteolysis of IGFBPs is believed to be the major
mechanism for the release of IGFs from IGFBP/IGF com-
plexes, generating fragments with reduced a⁄nity for IGFs
[8]. IGFBP protease activities have been reported to be
present in physiological £uids and media of cultured cells
di¡ering in their susceptibility against inhibitors, pH opti-
mum, requirements of cations, tissue and IGFBP speci¢city,
and their mechanism of activation and regulation [5]. Re-
cently, the disintegrin metalloprotease ADAM 12-S, the preg-
nancy-associated plasma protein A, and the complement com-
ponent C1s have been identi¢ed as IGFBP proteases [6^8].
Furthermore, it has been suggested that secreted lysosomal
proteases such as cathepsin D may be involved in the regu-
lation of extracellular IGFBP levels [9,10]. In the present
study, we report on the decrease in intracellular degradation
of endocytosed IGFBP-3 in ¢broblasts de¢cient for the lyso-
somal cysteine protease cathepsin L (CTSL) resulting in an
extracellular accumulation of IGFBP-3.
2. Materials and methods
2.1. Materials
Sodium [125I]iodine, [32P]dCTP, T7Quickprime kit, Percoll, and pre-
stained protein standard (Rainbow) were purchased from Amersham
Pharmacia Biotech (Freiburg, Germany). Recombinant human (rh)
IGF II from GroPep (Adelaide, Australia) was iodinated by the chlor-
amine T method. Non-glycosylated rhIGFBP-3, a generous gift from
Dr. A. Sommer (Celtrix, Santa Clara, CA, USA), and rhIGFBP-4 and
-6, kindly provided by Dr. J. Zapf (University Hospital Zurich, Swit-
zerland), were iodinated using Iodo-Gen (Pierce Chemical, Rockford,
IL, USA) as described [11]. Pansorbin (10% Staphylococcus aureus cell
suspension) was from Calbiochem-Novabiochem (Schwalbach, Ger-
many). Human kidney CTSL was from Biogenesis (Poole, UK). Re-
combinant IGFBP-1 and the rabbit antiserum against human IGFBP-
3 were purchased from UBI (Lake Placid, NY, USA).
2.2. cDNA probes
The rat IGFBP-3 cDNA clone pRBP-3-AR, and the rat IGFBP-4
cDNA clone pRBP-4-SH were kindly provided by Dr. Ling (La Jolla,
CA, USA [12]) and the ctsl cDNA was from Dr. M.M. Gottesman
(Bethesda, MD, USA). The 28S rRNA was detected with a comple-
mentary oligonucleotide [13].
2.3. Animals
Target disruption and generation of CTSL-de¢cient homozygous
mice (ctsl3/3) on a mixed B6/129/J background is described else-
where [14]. Age-matched C57/BL76 mice served as controls. The ani-
mals were maintained and killed according to institutional guidelines
in animal facilities of the University Medical Center, Freiburg, Ger-
many.
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2.4. Isolation and culture of mouse cells
Fibroblasts were prepared from skin biopsies of adult mice by in-
cubation in 10 mM phosphate-bu¡ered saline (PBS) containing 0.2%
collagenase III (Biochrom, Wertheim, Germany) and 2 U/ml dispase I
(Roche Molecular Biochemicals, Mannheim, Germany) for 3 h at
37‡C. The ¢ltered suspension was centrifuged, and the pellet was
resuspended in Dulbecco’s modi¢ed essential medium (DMEM) con-
taining penicillin/streptomycin supplemented with 10% fetal calf se-
rum (Gibco BRL, Grand Island, NY, USA)) and plated. For condi-
tioning, the washed cells were preincubated in DMEM containing
0.05% bovine serum albumin (DMEM/BSA) for 8 h and further in-
cubated in fresh DMEM/BSA for 24^72 h.
2.5. Subcellular fractionation
Mouse ¢broblasts grown in a 10 cm dish were incubated for 3 h
with [125I]IGFBP-3 (200 000 cpm/ml) at 37‡C. After removal of the
medium, unbound and cell surface-bound [125I]IGFBP-3 were dis-
placed by an acid wash (0.2 M acetic acid containing 0.5 M NaCl)
at pH 2.5 for 5 min. A postnuclear supernatant was prepared and
fractionated by Percoll (25%) as described [15]. One milliliter fractions
were collected and analyzed for radioactivity, density, and L-hexos-
aminidase activity [16]. Fractions 1^3, 4^6, and 7^9 were pooled
(pools I, II, and III, respectively) and after removal of Percoll, the
membranes were solubilized in PBS containing 0.2% Triton X-100 and
protease inhibitors (bu¡er B).
2.6. [125I]IGFBP-3 immunoprecipitation
After preabsorption with preimmune serum and Pansorbin, anti-
IGFBP-3 antiserum was added to the membrane extracts for 2 h at
4‡C followed by the addition of Pansorbin for 1 h. After centrifu-
gation, the immunocomplexes were washed in bu¡er B and 1 mM
PBS. The solubilized samples were separated by SDS^polyacryl-
amide gel electrophoresis (PAGE) and visualized by autoradiogra-
phy.
2.7. Determination of CTSL cleavage sites
Five micrograms of non-glycosylated IGFBP-3 were incubated with
10 Wg CTSL in 50 Wl 0.1 M Na-acetate bu¡er, pH 5.6, at 37‡C for 20
h and further analyzed as described [10].
2.8. IGFBP protease assay
Fifty microliters of conditioned medium adjusted to the indicated
pH were incubated with [125I]IGFBP-3 or -4 (15 000^20 000 cpm) at
37‡C for 6^18 h. After solubilization the samples were subjected to
SDS^PAGE and visualized by autoradiography [10] or phosphor-
imaging (Cyclone, Packard, Meriden, CT, USA).
2.9. Other methods
[125I]IGF II ligand blot analysis, isolation of total RNA from rat
liver or mouse ¢broblasts, and processing for Northern blot analysis
have previously been described [17].
3. Results
Inhibitors of cysteine proteases have been reported to pre-
vent the proteolysis of IGFBP-4 in conditioned medium from
cathepsin D-de¢cient mouse liver explants [18]. To determine
the IGFBP speci¢city, recombinant human 125I-labeled
IGFBP-1, -3, -4, and -6 were incubated in the presence and
in the absence of CTSL for 16 h at various pH values fol-
lowed by SDS^PAGE and autoradiography. No fragmenta-
tion of IGFBP-1 and -6 by CTSL was detected (not shown).
When non-glycosylated [125I]IGFBP-3 was incubated with
CTSL, two major fragments of 18 and 14 kDa were generated
over a broader pH range from 5.0 to 7.0 with a optimum at
pH 6.0 (Fig. 1). Microsequencing of a 17 kDa fragment (sep-
arated under reducing conditions instead of non-reducing con-
ditions as shown in Fig. 1) formed by large scale proteolysis
of IGFBP-3 by CTSL at pH 5.6 resulted in the sequence
IIIIKKGH, indicating isoleucine 172 as cleavage site. When
[125I]IGFBP-4 was used as a substrate for CTSL, optimal
activity was observed at pH 5.0 resulting in the formation
of 17 and 10 kDa IGFBP-4 fragments (Fig. 1).
To assess the role of CTSL in IGFBP degradation in vivo,
IGFBP levels were studied in conditioned medium from ¢bro-
blasts of CTSL-de¢cient mice by ligand blotting and com-
pared with the IGFBP pattern of mouse serum. The amount
of the 42/45 kDa IGFBP-3 doublet was found to be strongly
increased (2.7-fold, mean of four experiments estimated by
densitometry) compared with medium from control mouse
¢broblasts (Fig. 2). The abundance of the 26 kDa IGFBP
(presumably IGFBP-4) was about 1.8-fold higher in CTSL-
de¢cient cells whereas the activity of secreted L-hexosamini-
dase was comparable with control cells (2.9 vs. 4.0 mU/ml).
The identity of the IGFBPs could not be determined due to
the failure of tested antibodies to cross-react speci¢cally with
mouse IGFBPs. Northern blot analysis showed similar or
even higher intensities of the 2.6 kb speci¢c IGFBP-3 and -4
transcripts, respectively, in CTSL-de¢cient and control ¢bro-
blasts (Fig. 3) excluding higher IGFBP transcriptional rates in
CTSL-de¢cient cells. Reprobing of the IGFBP-4 blot with
Fig. 1. Proteolysis of IGFBP-3 and -4 by CTSL. [125I]IGFBP-3 and
-4 were incubated in the presence or absence of human CTSL (1 Wg
for 16 h or 0.5 Wg for 4 h, respectively) at the indicated pH at
37‡C. The reaction products were separated by SDS^PAGE (12.5%
acrylamide) and visualized by autoradiography. The position of the
molecular mass marker proteins (in kDa) are indicated.
Fig. 2. Ligand blot analysis. Control (+/+) and CTSL-de¢cient (3/
3) ¢broblasts were incubated in serum-free medium for 72 h. Ali-
quots of (A) the medium (0.3 ml) or (B) mouse serum (S) were ana-
lyzed by [125I]IGF II ligand blotting. This autoradiograph is repre-
sentative of four independent experiments.
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CTSL cDNA and the 28S rRNA complementary oligonucleo-
tide con¢rmed the ctsl gene targeting and equal loading of
RNA, respectively.
To determine whether proteases a¡ect the IGFBP-3 level in
the medium of CTSL-de¢cient ¢broblasts, IGFBP-3 protease
activity was assessed at pH 4.0, 5.6, and 7.0 in vitro. During
cell-free incubation at each pH distinct IGFBP-3 cleavage
pattern were observed but without di¡erences between media
from control and CTSL-de¢cient cells (not shown). In con-
trast, when primary ¢broblasts from control and CTSL-de¢-
cient mice were incubated with [125I]IGFBP-3 for 1^4 h at
37‡C, a continuous disappearance of the intact [125I]IGFBP-
3 in the medium was observed (Fig. 4). In parallel, the amount
of trichloroacetic acid-soluble radioactivity in the medium in-
creased with the incubation time (not shown) demonstrating
the continuous degradation of [125I]IGFBP-3 in the presence
of cells. Analysis of the solubilized ¢broblasts by SDS^PAGE
and autoradiography showed that similar amounts of intact
[125I]IGFBP-3 as well as various fragments of 25, 18, and 14
kDa were associated with control and CTSL-de¢cient cells
after an incubation period of 1 h. An additional 28 kDa
IGFBP-3 fragment was detected only in CTSL-de¢cient cells.
After 2 and 4 h of incubation weak signals of [125I]IGFBP-3
fragments were found in control cell extracts whereas intact
[125I]IGFBP-3 and its fragments were still detectable in CTSL-
de¢cient cells (Fig. 4). To de¢ne the intracellular site of
IGFBP-3 cleavage, postnuclear supernatants prepared from
control and CTSL-de¢cient ¢broblasts after an incubation
for 3 h at 37‡C with [125I]IGFBP-3 were fractionated by Per-
coll density gradient centrifugation. The density pro¢le and
the distribution of L-hexosaminidase, a lysosomal marker, are
Fig. 3. IGFBP mRNA expression in control and CTSL-de¢cient ¢-
broblasts. Total RNA (12.5 Wg RNA/lane) from primary control (+/
+), CTSL-de¢cient mouse ¢broblasts (3/3), and rat liver (rLi) was
analyzed for IGFBP-3 and -4 expression using radiolabeled cDNA
probes. The sizes of the hybridization bands (in kb) are indicated.
Ethidium bromide-stained 28S and 18S rRNAs of the same prepara-
tion were tested for equal RNA loading (not shown). As representa-
tive, the IGFBP-4 blot was stripped and rehybridized with labeled
CTSL cDNA and the complementary 28S rRNA oligonucleotide.
Fig. 4. Cell-dependent degradation of IGFBP-3. Control (+/+) and
CTSL-de¢cient ¢broblasts (3/3) were incubated for 1, 2, and 4 h
at 37‡C with [125I]IGFBP-3 (130 000 cpm per plate) in serum-free
medium. After removal of the medium, the washed cells were
scraped and collected by centrifugation. Aliquots of the medium
(13% of total) and the cells were solubilized and analyzed by SDS^
PAGE and autoradiography. An aliquot of [125I]IGFBP-3-contain-
ing medium incubated in the absence of cells was used as control.
The experiment was repeated with cells from three di¡erent prepara-
tions resulting in moderate alterations in the kinetics of
[125I]IGFBP-3 degradation but with similar di¡erences in cellular ac-
cumulated [125I]IGFBP-3.
Fig. 5. Subcellular localization of endocytosed [125I]IGFBP-3. Con-
trol (+/+) and CTSL-de¢cient ¢broblasts (3/3) were incubated for
3 h at 37‡C with [125I]IGFBP-3. The postnuclear supernatant was
subjected to Percoll density gradient centrifugation. The collected
fractions were tested for density (R) and L-hexosaminidase activity
in mU/ml (F) (A). The distribution of [125I]IGFBP-3 radioactivity
from both gradients are shown (B). The fractions 1^3, 4^6, and 7^9
were afterwards combined to prepare the membrane fractions I, II,
and III, respectively, which were used for immunoprecipitation of
[125I]IGFBP-3 (C).
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shown in Fig. 5A. The highest radioactivity values were esti-
mated in the light membrane fractions (fractions 7^9) of con-
trol cells comprising the endoplasmic reticulum, Golgi, plasma
membranes and endosomes [15]. In contrast, the total radio-
activity in all subcellular fractions from CTSL-de¢cient ¢bro-
blasts was about 2.5-fold higher (mean of two experiments)
than in fractions of control cells, showing two peaks in the
dense lysosomal (fractions 1^3) and in the light membrane
fraction (Fig. 5B). To explore the distribution of intact and
IGFBP-3 fragments, [125I]IGFBP-3 was immunoprecipitated
from solubilized membrane pools I, II, and III. The majority
of immunoreactive intact and [125I]IGFBP-3 fragments were
precipitated from the light membrane fraction (III) of control
cells (Fig. 5C). Both intact and [125I]IGFBP-3 fragments were
detected in a similar ratio in the fractions I, II, and III from
CTSL-de¢cient ¢broblasts.
4. Discussion
In this study we demonstrated that the cysteine protease
CTSL cleaves IGFBP-3 and -4 in vitro. The pH optimum
between 5.6 and 6.0 for the proteolysis of IGFBPs is similar
to that described for arti¢cial substrates [19]. CTSL as well as
the aspartyl protease cathepsin D are highly abundant, ubiq-
uitously expressed lysosomal enzymes which are secreted in
low amounts as inactive precursor forms in normal cells.
However, the physiological signi¢cance of secreted cathepsins
in the regulation of extracellular IGFBP proteolysis appears
to be questionable. In this study we have demonstrated that
CTSL plays an important role in the intracellular degradation
of IGFBP-3. Fibroblasts from CTSL-de¢cient mice are char-
acterized by (i) an extracellular accumulation of IGFBP-3,
and (ii) a transient accumulation of intact and proteolytic
fragments of endocytosed IGFBP-3 which is rapidly and com-
pletely degraded in normal mouse ¢broblasts. It appears that
the intracellular accumulation of IGFBP-3 a¡ects the uptake
of IGFBP-3 in CTSL-de¢cient cells suggesting rather limita-
tions in the transport capacity of a putative IGFBP-3 receptor
than pinocytotic uptake. Several membrane-associated pro-
teins and the type V transforming growth factor-L receptor
have been described as putative IGFBP-3 receptors [20^22].
Endocytosis of IGFBP-3 has also been reported in rat mega-
karyocytes [23] and cocultures of rat hepatocytes and Kup¡er
cells [13]. The identity of the IGFBP-3 receptor in these three
cell systems remains to be determined.
Upon subcellular fractionation of mouse ¢broblasts, we
showed that the endocytosed IGFBP-3 is transported via the
endosomal compartment to lysosomes for ¢nal degradation.
In rat megakaryocytes the endocytosed intact IGFBP-3 accu-
mulated in K-granules [23]. Interestingly, the present data
showed that endocytosed IGFBP-3 is completely degraded
with di¡erent kinetics in control and CTSL-de¢cient cells,
whereas puri¢ed CTSL or cathepsin D [10] generated in vitro
IGFBP-3 fragments of de¢ned sizes. This suggests that several
acidic proteases are involved in cellular IGFBP-3 degradation
which can compensate either the total de¢ciency of a single
protease such as CTSL or cathepsin D [18], or the partial
de¢ciency of several lysosomal enzymes [24]. Thus, the gen-
eration and transient accumulation of IGFBP-3 fragments
may be explained by the ine⁄cient initial cleavage(s) of
IGFBP-3 required for subsequent proteolytic steps which
can be overcome by other (cysteine) proteases with lower e⁄-
ciency. This is supported by the identi¢cation of one new
CTSL cleavage site in IGFBP-3, isoleucine 172, which was
not found in any of the previous studies [10,25,26].
In summary, our ¢ndings demonstrate that mouse ¢bro-
blasts are capable of endocytosing IGFBP-3 from extracellu-
lar £uid. This study also shows that CTSL is required but not
essential for an e⁄cient and rapid degradation of IGFBP-3
along the endocytic pathway. Whereas CTSL is supposed to
function in non-speci¢c terminal degradation of proteins in
lysosomes, recent studies investigating CTSL-de¢cient mice
have reported more speci¢c functions of CTSL in the process-
ing of the invariant chain of MHC II in cortical thymic epi-
thelial cells [27] and in the control of proliferation of hair
follicle epithelial cells and basal keratinocytes [14]. Since
growth factors including IGF I play an essential role in the
balance between proliferation and di¡erentiation of epithelial
cells [28], the sequestration of IGFs by accumulating IGFBP-3
derived from CTSL-de¢cient dermal ¢broblasts may shift the
balance toward proliferation causing epidermal and hair fol-
licle hyperplasia.
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